Login to Your Account

ArQule Lung Cancer Study Enrollment Halted for Safety

By Catherine Shaffer
Staff Writer

Thursday, August 30, 2012
ArQule Inc.'s stock plummeted 18.5 percent Wednesday when its partner Kyowa Hakko Kirin Co. Ltd., of Tokyo, suspended patient enrollment in its ongoing Phase III ATTENTION trial of tivantinib in non-small-cell lung cancer.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription